For the year ending 2025-12-31, BIIB has $29,439,500K in assets. $11,182,700K in debts.
| Balance Sheets | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 3,008,500 | 2,375,000 | 1,049,900 | 3,419,300 |
| Current portion of marketable securities | 807,200 | - | 0 | 1,473,500 |
| Accounts receivable, net of allowance for doubtful accounts of 3.0 and 2.2, respectively | 1,342,400 | 1,404,800 | 1,664,100 | 1,705,000 |
| Due from anti-cd20 therapeutic programs | 524,600 | 464,000 | 435,900 | 431,400 |
| Inventory | 2,168,100 | 2,460,500 | 2,527,400 | 1,344,400 |
| Other current assets | 1,123,300 | 752,500 | 1,182,000 | 1,417,600 |
| Total current assets | 8,974,100 | 7,456,800 | 6,859,300 | 9,791,200 |
| Marketable securities | 431,900 | - | 0 | 705,700 |
| Property, plant and equipment, net | 3,055,400 | 3,181,300 | 3,309,700 | 3,298,600 |
| Operating lease assets | 265,400 | 356,400 | 420,000 | 403,900 |
| Intangible assets, net | 9,178,500 | 9,691,200 | 8,363,000 | 1,850,100 |
| Goodwill | 6,491,100 | 6,478,900 | 6,219,200 | 5,749,000 |
| Deferred tax asset | 292,500 | 324,200 | 928,600 | 1,226,400 |
| Investments and other assets | 750,600 | 560,500 | 745,000 | 1,529,200 |
| Total assets | 29,439,500 | 28,049,300 | 26,844,800 | 24,554,100 |
| Current portion of notes payable | 0 | 1,748,600 | 150,000 | 0 |
| Taxes payable | 114,800 | 548,300 | 257,400 | 259,900 |
| Accounts payable | 432,000 | 424,200 | 403,300 | 491,500 |
| Accrued expense and other | 2,802,600 | 2,807,700 | 2,623,600 | 2,521,400 |
| Total current liabilities | 3,349,400 | 5,528,800 | 3,434,300 | 3,272,800 |
| Notes payable | 6,286,800 | 4,547,200 | 6,788,200 | 6,281,000 |
| Deferred tax liability | 507,600 | 190,500 | 641,800 | 334,700 |
| Long-term operating lease liabilities | 290,400 | 334,500 | 400,000 | 333,000 |
| Other long-term liabilities | 748,500 | 732,300 | 781,100 | 944,200 |
| Total liabilities | 11,182,700 | 11,333,300 | 12,045,400 | 11,165,700 |
| Common stock, par value 0.0005 per share | 100 | 100 | 100 | 100 |
| Additional paid-in capital | 863,100 | 569,400 | 302,500 | 73,300 |
| Accumulated other comprehensive income (loss) | -182,000 | -136,200 | -153,700 | -164,900 |
| Retained earnings | 20,552,700 | 19,259,800 | 17,627,600 | 16,466,500 |
| Treasury stock, at cost 23.8 million and 23.8 million shares, respectively | 2,977,100 | 2,977,100 | 2,977,100 | 2,977,100 |
| Total biogen inc. shareholders equity | - | - | 14,799,400 | 13,397,900 |
| Noncontrolling interests | - | - | 0 | -9,500 |
| Total equity | 18,256,800 | 16,716,000 | 14,799,400 | 13,388,400 |
| Total liabilities and equity | 29,439,500 | 28,049,300 | 26,844,800 | 24,554,100 |
BIOGEN INC. (BIIB)
BIOGEN INC. (BIIB)